Mode
Text Size
Log in / Sign up

Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fracturesAdding Antibiotics to Bone Surgery Didn't Lower Infection Risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Adding intrawound tobramycin to vancomycin did not reduce deep infection risk in high-risk tibial fractures.

This randomized clinical trial enrolled 1660 adults with an operatively treated periarticular tibial fracture, either tibial plateau or pilon, who met one of three criteria for elevated infection risk. The study was conducted across 39 US trauma centers. Participants received definitive fixation at the time of intervention. The primary exposure was the addition of intrawound tobramycin powder to intrawound vancomycin powder delivered during surgery. The comparator group received intrawound vancomycin powder alone. Both groups received the powder at the time of definitive fracture fixation.

The primary outcome was deep surgical site infection requiring surgical management within 182 days of definitive fracture fixation. The rate of this outcome was 7.4% in the tobramycin plus vancomycin group versus 6.6% in the vancomycin alone group. Specifically, 51 of 753 participants in the tobramycin plus vancomycin group experienced the primary outcome, while 47 of 775 participants in the vancomycin alone group experienced it. The effect size was a hazard ratio of 1.11. The 95% Bayesian credible interval for this hazard ratio ranged from 0.75 to 1.66. The posterior probability of superiority was 29.7%. These data indicate no reduction in the primary outcome with the addition of tobramycin.

Key secondary outcomes included deep surgical site infections with pathogens that were gram-negative only, deep surgical site infections with at least one pathogen that was gram-positive, deep surgical site infections with polymicrobial cultures, deep surgical site infections with negative culture results, and cellulitis or skin infections treated only with antibiotics. The study report did not provide specific numerical results for these secondary outcomes in the provided data. The analysis focused on the primary composite of deep infection requiring surgical management.

Safety and tolerability findings were not reported in the provided data. There were no reported adverse events, serious adverse events, discontinuations, or specific tolerability metrics. The study design was open-label with assessor-masked assessment of outcomes. Funding or conflicts of interest were not reported. The absence of safety data limits the ability to assess the risk-benefit profile of adding tobramycin powder in this specific population.

Prior landmark studies in orthopedic infection prevention have often focused on vancomycin powder as a standard adjunct. This trial suggests that adding tobramycin does not confer additional benefit over vancomycin alone for preventing deep surgical site infections in high-risk tibial fractures. The hazard ratio of 1.11 suggests a potential trend toward higher risk, although the Bayesian credible interval includes values below 1.0. The posterior probability of superiority was low at 29.7%, indicating that the data do not support the efficacy of the combination therapy for the primary endpoint.

Methodological limitations include the open-label nature of the trial, which may introduce performance bias, although assessors were masked. The sample size of 1660 participants across 39 centers provides a robust estimate for the primary outcome. However, the lack of reported safety data is a significant limitation. Potential biases related to the open-label design and the specific criteria for elevated infection risk may influence generalizability to other fracture types or risk profiles.

Clinical implications suggest that adding intrawound tobramycin powder to vancomycin powder at the time of definitive fixation did not reduce deep surgical site infections compared with vancomycin powder alone. Physicians should not alter their standard practice of using vancomycin powder alone based on these results. The data do not support the routine addition of tobramycin for this indication. Further research may be needed to identify subgroups that might benefit from combination therapy or to clarify safety concerns.

Questions remain unanswered regarding the safety profile of the combination therapy, as adverse events were not reported. It is unclear if the lack of efficacy extends to other fracture types or lower-risk populations. The study did not address long-term outcomes beyond 182 days. Clinicians should continue to follow established protocols for infection prevention in periarticular tibial fractures without assuming added benefit from tobramycin.

Imagine breaking your leg near the knee or ankle. The bone is shattered. You need surgery to put it back together. And your doctor tells you that because of your health or the injury itself, you have a higher than normal chance of getting a serious infection.

That is a scary place to be.

Infections after bone surgery are not just painful. They can mean more operations, longer hospital stays, and months of antibiotics. For years, surgeons have been looking for better ways to prevent them.

One method gained a lot of attention. During surgery, doctors sprinkle antibiotic powder directly into the wound before closing it up. The idea makes sense. Put the medicine right where the germs are.

The most common powder used is vancomycin. It works well against certain bacteria. But some infections are caused by different types of germs. So researchers wondered: what if we add a second antibiotic powder that targets those other bacteria?

A new study tested exactly that. And the results surprised many people.

What the TOBRA Trial Tested

The study is called the TOBRA trial. It took place at 39 trauma centers across the United States. Researchers enrolled over 1,500 adults who had surgery for tibial plateau or pilon fractures. These are serious breaks near the knee or ankle joint.

Every patient in the study had at least one factor that put them at higher risk for infection. This could include things like diabetes, smoking, or the wound being open at the time of injury.

Half of the patients got the standard treatment. Surgeons placed vancomycin powder into the wound before closing it. The other half got vancomycin plus a second antibiotic powder called tobramycin.

Tobramycin targets a different group of bacteria than vancomycin. The hope was that using both would cover more types of germs and lower infection rates.

The Results Were Clear

After six months, researchers checked how many patients developed a deep surgical site infection. This is an infection that goes below the skin into the bone or metal hardware. These infections almost always require another surgery to clean out.

In the group that got only vancomycin, 6.6 percent of patients developed a deep infection.

In the group that got both vancomycin and tobramycin, 7.4 percent developed a deep infection.

That difference is not statistically meaningful. In plain English, adding the second antibiotic did not help. It may have even made things slightly worse, though the numbers are close enough that this could be due to chance.

This means more antibiotics are not always the answer.

The researchers also looked at infections caused by gram-negative bacteria, which are the type that tobramycin targets. Even there, adding tobramycin did not make a difference.

Why Adding a Drug Didn't Help

This result might seem strange. If tobramycin kills certain bacteria, why didn't it lower infections from those bacteria?

There are a few possible reasons.

First, the vancomycin powder alone may already be doing a good job. The infection rate in the vancomycin-only group was about 6.6 percent. That is lower than what some earlier studies predicted for high-risk patients.

Second, putting powder into a wound is not the same as giving antibiotics through an IV or a pill. The powder stays in one spot. It may not spread evenly through the wound. Some areas might get a high dose while others get almost none.

Think of it like salting a steak. If you sprinkle salt on one spot, that spot gets salty. But the rest of the steak stays plain. The same thing can happen with antibiotic powder in a wound.

Third, infections are complicated. They depend on many factors beyond just which antibiotics you use. The patient's overall health, how well the blood flows to the injured area, and how clean the surgery is all play a role.

What This Means for Patients

If you or someone you love needs surgery for a serious leg fracture, this study offers an important lesson.

The standard approach of using vancomycin powder alone appears to be reasonable. Adding a second antibiotic powder does not seem to provide extra protection. It may add cost and potential side effects without any benefit.

But here is the catch. This study only looked at one specific situation: high-risk tibial fractures treated with surgery. The results may not apply to other types of bone surgery or other antibiotics.

If you are having bone surgery, talk to your doctor about infection prevention. Ask what methods they use. Ask about your personal risk factors. Every patient is different.

The Limits of This Research

No study is perfect. This one has some important limitations.

The trial was open-label. That means the surgeons knew which treatment each patient received. This could have influenced how they cared for patients after surgery.

Also, the study only followed patients for six months. Some infections can show up later than that.

And while the study was large, it may not have been large enough to detect a very small benefit from adding tobramycin. If the benefit is tiny, it might not be worth the extra cost and risk anyway.

What Happens Next

The TOBRA trial gives surgeons clear guidance. For now, there is no evidence to support using both vancomycin and tobramycin powder in these fractures.

Researchers will continue to look for better ways to prevent infections after bone surgery. This might include different combinations of antibiotics, different ways of delivering them, or non-antibiotic approaches.

Science moves slowly for a reason. Every new idea needs to be tested carefully. What sounds good in theory does not always work in practice.

This study is a reminder that more medicine is not always better medicine. Sometimes the best treatment is the one that has been proven to work, even if it seems simpler.

Study Details

Study typeRct
Sample sizen = 1,660
EvidenceLevel 2
PublishedMay 2026
View Original Abstract ↓
IMPORTANCE: Previous research has suggested that intrawound vancomycin powder reduces deep surgical site infections among patients with periarticular tibial fractures at high risk of infection. It is unknown whether the addition of tobramycin powder further decreases infection rates. OBJECTIVE: To compare whether the combination of tobramycin plus vancomycin vs vancomycin alone delivered as intrawound powder at the time of definitive fixation reduces deep surgical site infections. DESIGN, SETTING, AND PARTICIPANTS: Open-label, assessor-masked, randomized clinical trial conducted at 39 US trauma centers. Eligible patients were adults with an operatively treated periarticular tibial fracture (either tibial plateau or pilon) who met 1 of 3 criteria for elevated infection risk. Enrollment occurred between June 18, 2021, and December 12, 2024 (final follow-up, July 15, 2025). INTERVENTIONS: Intrawound tobramycin (1.2 g) plus vancomycin (1.0 g) powder vs intrawound vancomycin (1.0 g) powder delivered at the time of definitive fixation. MAIN OUTCOMES AND MEASURES: The primary outcome was a deep surgical site infection requiring surgical management within 182 days of definitive fracture fixation. Secondary outcomes included deep surgical site infections with pathogens that were gram-negative only, deep surgical site infections with at least 1 pathogen that was gram-positive, deep surgical site infections with polymicrobial cultures, deep surgical site infections with negative culture results, and cellulitis or skin infections treated only with antibiotics. RESULTS: Among the 1660 participants randomized, 1528 (mean age, 47.0 [SD, 14.3] years; 603 female [39.5%]; 925 male [60.5%]) were included in the primary analysis. Deep surgical site infections occurred in 51 of 753 participants (182-day probability, 7.4%) in the tobramycin plus vancomycin group and 47 of 775 participants (182-day probability, 6.6%) in the vancomycin alone group (hazard ratio, 1.11; 95% bayesian credible interval, 0.75-1.66; posterior probability of superiority, 29.7%). The threshold required for superiority was not reached for any secondary outcome. CONCLUSIONS AND RELEVANCE: Among patients with operatively treated periarticular tibial fractures at high risk of infection, adding intrawound tobramycin powder to vancomycin powder at the time of definitive fixation did not reduce deep surgical site infections compared with vancomycin powder alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02227446.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.